Curasight Denmark

Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT belonging to Curasight's treatment platform.Initiation of the study marks a key milestone with Curasight now in clinical development with both its diagnostic (uTRACE®) and therapeutic (uTREAT®) platformsDosing of first patient expected Q4 2025View original content:https://www.prnewswire.co.uk/news-releases/curasight-announces-acceptance-of-clinical-trial-application-cta-for-phase-1-trial-with-utreat-in-brain-cancer-patients-302538481.html